MedElevator
Войти в исследования ESMO real world data and digital oncology · 2026
HeCOG Cancer Biobank and Registry: a nationwide real-world resource for translational oncology research.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fountzilas E, Papadopoulou K, Koliou G-A, Papapavlou T, Pectasides D, Christodoulou C, Samantas E, Bafaloukos D, Aravantinos G, Kosmidis P A, Kalofonos H P, Sgouros J, Papakostas P, Razis E, Economopoulos T, Zamboglou N, Koutras A, Pentheroudakis G, Zagouri F, Linardou H, Christopoulou A, Papamichael D, Skarlos P, Batistatou A, Goussia A, Kourea H P, Pervana S, Tzaida O, Petraki K, Pavlakis K, Arapantoni-Dadioti P, Koletsa T, Kotoula V, Pavlidis N, Gogas H, Psyrri A, Fountzilas G
Аннотация
BACKGROUND: Long-standing cooperative oncology groups are uniquely positioned to generate high-quality real-world data in diverse tumor types. The Hellenic Cooperative Oncology Group (HeCOG), a nonprofit scientific organization, has established a multi-institutional clinical database and biobank to support translational cancer research and precision oncology initiatives. Our aim was to describe the structure, governance and operation of HeCOG Biobank and patient registry.
MATERIALS AND METHODS: The HeCOG clinical database is a centralized, web-based platform that supports interventional, observational, real-world and translational studies across affiliated institutions. Clinical data are linked to biospecimens stored in the HeCOG Biobank, preserved at the Laboratory of Molecular Oncology. Biospecimen collection, processing, storage, and data handling are governed by standardized operating procedures.
RESULTS: To date, the registry includes >54 000 patients with diverse tumors, enrolled retrospectively and prospectively. The associated biobank comprises >17 000 formalin-fixed paraffin-embedded tumor tissue samples and >6000 blood-derived specimens. The largest tissue collections are from breast, colorectal, and lung cancer. Molecular and histopathological biomarker data are also available for several thousand patients within the registry. Biospecimens are uniquely coded and linked to pseudonymized longitudinal clinical, histopathological, and molecular data. Ongoing expansion includes digital pathology and radiological imaging datasets, further enhancing the translational potential of the resource.
CONCLUSIONS: The HeCOG Biobank and the accompanying clinical database have evolved into a valuable resource for translational cancer research in Greece. Through the ongoing integration of digital pathology, imaging data, and artificial intelligence-based approaches it provides a strong basis for precision oncology and collaborative national and international research.
MATERIALS AND METHODS: The HeCOG clinical database is a centralized, web-based platform that supports interventional, observational, real-world and translational studies across affiliated institutions. Clinical data are linked to biospecimens stored in the HeCOG Biobank, preserved at the Laboratory of Molecular Oncology. Biospecimen collection, processing, storage, and data handling are governed by standardized operating procedures.
RESULTS: To date, the registry includes >54 000 patients with diverse tumors, enrolled retrospectively and prospectively. The associated biobank comprises >17 000 formalin-fixed paraffin-embedded tumor tissue samples and >6000 blood-derived specimens. The largest tissue collections are from breast, colorectal, and lung cancer. Molecular and histopathological biomarker data are also available for several thousand patients within the registry. Biospecimens are uniquely coded and linked to pseudonymized longitudinal clinical, histopathological, and molecular data. Ongoing expansion includes digital pathology and radiological imaging datasets, further enhancing the translational potential of the resource.
CONCLUSIONS: The HeCOG Biobank and the accompanying clinical database have evolved into a valuable resource for translational cancer research in Greece. Through the ongoing integration of digital pathology, imaging data, and artificial intelligence-based approaches it provides a strong basis for precision oncology and collaborative national and international research.